ClinicalTrials.gg
RecruitingNCT05516277Updated Apr 15, 2026

Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder

An interventional study of Behavioral Sleep Education Intervention in Posttraumatic Stress Disorder, Insomnia and Cardiovascular Diseases, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
167
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stress Disorders, Post-Traumatic by University of California, Los Angeles — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of California, Los Angeles.

Planned enrollment
2nd of 17
167 · median 60
Started
2023
with 3 others
No phase
13 of 18
3 open now
Registered
11th of 18
by date

Among the 18 studies in Stress Disorders, Post-Traumatic by University of California, Los Angeles, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2023, is one of 13 with no phase, and was the 11th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 18 studies in Stress Disorders, Post-Traumatic by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stress Disorders, Post-Traumatic by University of California, Los Angeles, or all of them as a file.
02

Study summary

This pilot pre-post trial will address a gap in knowledge related to addressing modifiable risk factors for cardiometabolic disease through treating residual insomnia, sleep difficulties that remain after successful treatment of another condition, in the context of PTSD in understudied older adults. This study provides a non-medication treatment for PTSD called Cognitive Processing Therapy (CPT) followed by a non-medication sleep education and treatment program (Cognitive Behavioral Therapy for Insomnia, CBT-I) for sleep problems that remain after completing PTSD treatment in older adults with PTSD. The aims of this project are to evaluate 1) the added benefits of treating residual insomnia on sleep and PTSD symptoms; 2) the added benefits of treating residual insomnia following CPT on cardiometabolic risk biomarkers and quality of life; and 3) the durability of the sleep, PTSD, cardiometabolic and quality of life benefits of treating residual insomnia following CPT at 6-month follow-up in older adults with PTSD.

Read the detailed description

Both insomnia and Post Traumatic Stress Disorder (PTSD) are independent risk factors for cardiometabolic diseases; the leading causes of morbidity and mortality in the US for which the growing geriatric population is at elevated risk. PTSD and insomnia disorder frequently co-occur yet require unique treatments, as sleep difficulties are one of the most common residual symptoms that remain after completing an evidence-based PTSD treatment.

This pilot pre-post trial provides a non-medication treatment for PTSD called Cognitive Processing Therapy (CPT) followed by a non-medication sleep education and treatment program (Cognitive Behavioral Therapy for Insomnia, CBT-I) for sleep problems that remain after completing PTSD treatment in older adults with PTSD. Individuals over 50 years of age, who have received care at the VA Greater Los Angeles Healthcare System, and who have been exposed to a stressful or traumatic life event will be recruited for this study.

Participants will be asked to complete a baseline evaluation that involves (a) being asked questions about health, medications, personal information, quality of life, sleep patterns and habits, mood, and stressful/traumatic experiences; (b) wearing a blood pressure monitor at home for 24 hours; (c) wearing a continuous glucose monitor sensor that contains a small filament (a thread-sized needle) inserted into the upper arm or abdomen for 7 consecutive days; (d) wearing a wristwatch device that measures sleep/wake patterns for 7 consecutive days; and (e) completing a daily sleep diary for 7 consecutive days. Participants may also be screened for sleep apnea with a portable sleep apnea monitoring device with sensors worn on the wrist, index finger and chest for one night.

Information from the baseline evaluation and medical records will be reviewed by the research team to determine whether an individual is eligible and likely able to complete all future study activities. Participants will be contacted to be advised of their study eligibility status. If eligible after the baseline assessment, study staff will review future study activities and confirm the participant's interest in continuing in the study. All eligible and interested participants will then receive an evidence-based PTSD treatment (CPT; 12 sessions). Following completion of the PTSD treatment, participants will receive a sleep education program (CBT-I; 5 sessions). For eligible individuals, participation in this research will last about 11 months.

Main study outcomes assessments from the baseline evaluation will be repeated three times: (1) one week after completion of the PTSD treatment; (2) one week after completion of the sleep education program; and (3) 6-months after the sleep education program ends. Data will be analyzed using "intention to treat" principles, using appropriate statistical methods for pilot clinical trials.

The investigators hope to determine how these treatment programs affect health in older adults with PTSD and insomnia. Findings from this pilot study will expand our understanding of the relationships between evidence-based insomnia and trauma treatments and key outcomes of sleep, PTSD symptoms, cardiometabolic health and quality of life in older adults with PTSD and insomnia while informing future research.

03

Conditions studied

  • Posttraumatic Stress Disorder
  • Insomnia
  • Cardiovascular Diseases
  • Metabolic Disease

Keywords

  • Quality of Life
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Community-dwelling Veterans aged 50 years and older
  • Received care from a Veterans Health Administration (VHA) facility in the prior year
  • Diagnosis of PTSD
  • Diagnosis of insomnia disorder
  • Lives within a 50-mile radius of the research offices at the VA Sepulveda Ambulatory Care Center

Exclusion criteria

Exclusion Criteria:

  • Active substance use or in recovery with less than 90 days of sobriety
  • Too ill to engage in the study procedures (e.g., unable to attend the in-person meetings)
  • Unable to self-consent to participate
  • Unstable housing (as this will impact the research team's ability to retrieve costly and difficult to replace monitoring equipment)
  • Severe cardiovascular or respiratory disease (e.g., ventilatory failure, CHF)
  • Unstable medical or psychiatric disorders (which are a for behavioral treatment of insomnia)
  • Comorbid sleep disorders (i.e., central sleep apnea syndrome, diagnosed narcolepsy or circadian rhythm sleep-wake phase disorders) based on medical record review and baseline assessment data, or untreated, severe sleep disordered breathing (SDB) as assessed via WatchPAT or previous clinical evaluation (apnea-hypopnea index [AHI] ≥ 30; or AHI ≥ 15 plus Epworth Sleepiness Scale [ESS] score ≥ 10) that better explain sleep difficulties
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
167 participants (estimated)

Study arms

  • Experimental
    Behavioral Sleep Education Intervention

    Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.

    Behavioral: Behavioral Sleep Education Intervention

Interventions

  • BehavioralBehavioral Sleep Education Intervention

    Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.

    Also known as: Cognitive Behavioral Therapy for Insomnia

06

What researchers measure

Primary outcomes

  1. Consensus sleep diary questionnaire

    Self-reported sleep quality assessed with the Consensus sleep diary, a brief patient questionnaire evaluating multiple aspects of sleep quality including sleep onset latency (time to fall asleep in minutes) and sleep efficiency percentage (time asleep in minutes/time in bed in minutes x 100).

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  2. PTSD Checklist for DSM-5 (PCL-5)

    The PCL-5 is a self-report PTSD severity questionnaire evaluating multiple aspects of PTSD symptoms. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items. A higher score indicates more severe PTSD symptoms.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  3. 24-hr ambulatory blood pressure monitoring (ABPM) blood pressure variability

    ABPM is an assessment of hypertension, a cardiometabolic disease, and blood pressure patterns across the 24-hour period. We will assess within-subject blood pressure variability via standard deviation across 24-hours.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  4. 24-hr ambulatory blood pressure monitoring (ABPM) systolic/diastolic loads

    ABPM is an assessment of hypertension, a cardiometabolic disease, and blood pressure patterns across the 24-hour period. We will assess systolic/diastolic loads via percentage of elevated values across 24-hours.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  5. 24-hr ambulatory blood pressure monitoring (ABPM) change in blood pressure day to night

    ABPM is an assessment of hypertension, a cardiometabolic disease, and blood pressure patterns across the 24-hour period. We will assess change in blood pressure from day to night (day-night).

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  6. WHOQOL-BREF questionnaire

    Self-reported quality of life assessed with a brief patient questionnaire evaluating aspects of quality of life across four domains: 1) Physical health, 2) Psychological, 3) Social relations, and 4) Environment. Mean scores for each domain range from 4-20, which are multiplied by 4 to transform the domain score into a scaled score that is comparable to the full WHOQOL-100 measure. A higher score indicated higher quality of life.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

Secondary outcomes

  1. Homeostatic Model Assessment of Insulin Resistance (HOMA)

    HOMA is an assessment of insulin resistance, a cardiometabolic disease risk factor

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  2. Hemoglobin A1c (HbA1c)

    HbA1c is an assessment of hyperglycemia, a cardiometabolic disease.

    Time frame: Change from baseline to 6 months after completion of sleep intervention

  3. Body Mass Index (BMI)

    BMI is a measure body composition, a cardiometabolic disease risk factor.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  4. Central adiposity

    Hip-to-waist ratio is a measure of central adiposity, a cardiometabolic disease risk factor.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  5. Actigraphy

    Actigraphy is a wrist-watch style device with an imbedded accelerometer that measures movement to define sleep/wake patterns including sleep onset latency (time to fall asleep) and sleep efficiency (time asleep/time in bed x 100).

    Time frame: Change from baseline to 1 week after completion of sleep intervention

  6. Dyslipidemia

    Fasting serum lipids are measures of dyslipidemia, a cardiometabolic disease.

    Time frame: Change from baseline to 1 week after completion of sleep intervention

07

Study locations

1 of 1 sites recruiting
  • VA Greater Los Angeles Healthcare System
    North Hills, California 91343, United States
    Recruiting
    • Monica Kelly, PhD · Contactmonica.kelly2@va.gov · 818-891-7711
    • Monica Kelly, PhD · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We do not plan to make individual participant data (IPD) available to other researchers as this is a pilot study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 47 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2022
First posted
Aug 25, 2022
StartActual
Apr 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05516277
Responsible party
Monica R. Kelly, PhD, DBSM (Assistant Professor, University of California, Los Angeles) — Principal investigator
First posted
Aug 25, 2022
Start date
Apr 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 15, 2026

Study contacts

Monica Kelly, PhD
Contact
monica.kelly2@va.gov
818-891-7711 ext. 36066
Monica Kelly, PhD
principal investigator · UCLA / VA Greater Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion